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S UMMA R Y
S E T T I NG : The World Health Organization (WHO)
recommends the inclusion of pyrazinamide (PZA) in
treatment regimens for multidrug-resistant tuberculosis
(MDR-TB) unless resistance has been confirmed.
OB J E C T I V E : To investigate the association between
PZA susceptibility and MDR-TB treatment outcome
among patients treated with a PZA-containing regimen
and whether the duration of the intensive phase of the
PZA-containing regimen affected treatment outcome.
DE S I GN : We conducted a retrospective cohort study
including all eligible MDR-TB patients starting treat-
ment in 2003–2013 in the TB programme in Karakal-
pakstan, Uzbekistan. PZA drug susceptibility testing
(DST) using liquid culture was performed, and outcomes
were classified according to the WHO 2013 definitions.
R E SU LT S : Of 2446 MDR-TB patients included, 832
(34.0%) had an available baseline PZA DST result, 612
(73.6%) of whom were PZA-resistant. We found no
association between treatment success and PZA suscep-
tibility (adjusted odds ratio [aOR] 0.86, 95%CI 0.51–
1.44, P ¼ 0.6) in patients treated with PZA. Further-
more, among patients with no baseline PZA DST result,
no evidence was seen of an association between
treatment success and PZA treatment duration (aOR
0.86, 95%CI 0.49–1.51, P¼ 0.6).
CONC LU S I ON : Treatment of MDR-TB with a standard
PZA regimen does not appear to improve treatment
outcomes, regardless of PZA susceptibility or duration
of treatment.
K E Y WORD S : MDR-TB; PZA; Central Asia; treatment
outcome; drug resistance
A NATIONAL SURVEY IN UZBEKISTAN in 2011
identified multidrug-resistant tuberculosis (MDR-TB;
defined as tuberculosis [TB] resistant to at least
rifampicin [RMP] and isoniazid [INH], the two main
drugs used to treat drug-susceptible TB) in 23% of
new cases and 62% of retreatment cases.1 In
Karakalpakstan, a semi-autonomous republic in
Uzbekistan, pyrazinamide (PZA) resistance has been
reported in 63% of MDR-TB cases.2 A recent meta-
analysis estimated that 61% of patients with MDR-
TB worldwide had PZA resistance, which equates to
270 000 cases annually.3
The World Health Organization (WHO) recom-
mendation is to include PZA in an MDR-TB regimen
unless evidence of resistance exists.4 PZA acts
predominantly as a sterilising agent on semi-dormant
mycobacteria,5 and reduces the required treatment
duration in drug-susceptible TB.6 The main thera-
peutic effect in drug-susceptible TB occurs during the
first 2 months of treatment,6 but whether the same is
applicable for MDR-TB is not known.4,6–8 PZA has
shown synergistic effects with other anti-tuberculosis
drugs,9–11 which has resulted in its retention in the
shorter WHO-recommended MDR-TB regimen, as
well as in several novel regimens under evalua-
tion.4,12–15 Difficulties exist with PZA drug suscep-
tibility testing (DST) using the standard phenotypic
method of the BACTECe MGITe (Mycobacteria
Growth Indicator Tube) 960 System, as reports have
often shown uncertain reproducibility and reliability,
with testing prone to false resistance results.16–18
A major factor influencing the WHO recommen-
dation is a recent meta-analysis showing an associa-
tion between successful outcomes and PZA
susceptibility among MDR-TB patients treated with
PZA-containing regimens.19 Three small primary
studies that assessed the association of PZA resistance
with treatment outcomes showed conflicting re-
sults.20–22 No larger primary study is available, and
routine PZA DSTwas not an inclusion criterion in the
meta-analysis.19
The primary aim of the present study was to assess
Correspondence to: Johanna Kuhlin, London School of Hygiene & Tropical Medicine, Keppel St, Bloomsbury, London
WC1E 7HT, UK. e-mail: johanna.kuhlin@hotmail.com
Article submitted 15 July 2017. Final version accepted 18 December 2017.
the effect of PZA susceptibility on treatment outcome
among MDR-TB patients treated with an intensive-
phase regimen containing PZA within the drug-
resistant TB (DR-TB) programme in Karakalpakstan,
Uzbekistan. We hypothesised that treatment out-
comes would be better in PZA-susceptible than PZA-
resistant disease. We further assessed the effect of
PZA treatment duration on outcomes among patients
with PZA strains of unknown resistance or PZA-
resistant strains.
STUDY POPULATION AND METHODS
Drug-resistant tuberculosis programme in
Karakalpakstan
Me´decins Sans Frontie`res (MSF) and the Ministry of
Health, Uzbekistan, have been collaborating since
2003 to provide treatment for DR-TB in Karakalpak-
stan. Three phases, beginning in 2003, 2009 and
2012, reflect changing treatment protocols.23–25 DST
for all drugs was performed initially at the Suprana-
tional Reference Laboratory in Borstel, Germany, and
later in Karakalpakstan (Appendix Table A.1*). PZA
was routinely included in MDR-TB regimens, but
could be stopped according to the prevailing treat-
ment protocol at any time if PZA DST showed
resistance when the results became available (under
the 2003 and 2009 programmes), or after the
intensive phase in PZA-resistant patients (under the
2012 programme). Data were continuously collected
in an electronic database (EpiInfoe; Centers for
Disease Control and Prevention, Atlanta, GA, USA
and Excelw 2013; MicroSoft, Redmond, WA, USA).
Study population
Patients with records in the databases from 2003 to
March 2016 were screened using three inclusion
criteria: anti-tuberculosis treatment initiated between
October 2003 and September 2013; microbiological-
ly confirmed diagnosis of pulmonary MDR-TB using
phenotypic DST; and documented treatment out-
come. Inclusion was censored in September 2013 to
allow for 30 months of treatment. A diagnostic
sputum sample was defined as a sample submitted
before treatment started or up to 7 days later.
Exclusion criteria were as follows: no outcome
defined based on the WHO 2013 reporting frame-
work;26 outcome ‘not evaluated’ according to the
2013 reporting framework; never having started an
MDR-TB regimen based on WHO 2016 guidelines;4
human immunodeficiency virus (HIV) positivity; and
microbiologically confirmed extensively drug-resis-
tant TB (XDR-TB).
Definitions
We calculated the number of (non-PZA) drugs to
which the strain was resistant at diagnosis as the sum
of resistance to INH, RMP, ethambutol (EMB),
streptomycin (SM), ofloxacin (OFX), kanamycin
(KM) and capreomycin (CPM). If DST results against
a drug were unavailable, the strain was assumed to
have unknown resistance to the drug in question.
Patients with MDR-TB strains were either known to
be susceptible or had unknown DST results against
the second-line drugs (SLDs) OFX, KM and CPM.
Pre-XDR-TB strains had confirmed resistance to
either OFX or both KM and CPM. XDR-TB strains
had confirmed resistance to OFX and at least one of
KM and CPM.
Potentially effective drugs, excluding PZA, were
each counted as 1 if DST showed susceptibility or was
not performed (see Appendix). Acquired resistance
from follow-up DST was taken into account in the
monthly calculations; the median in the intensive
phase was also estimated. DST for RMP, INH, EMB,
OFX, KM, CPM, and SM was included. DST for
ethionamide, para-aminosalicylic acid and cycloser-
ine was not considered due to reports of unreliable
results;27 universal susceptibility to these agents was
an inherent assumption. OFX-resistant specimens
were also considered resistant to levofloxacin and
moxifloxacin (MFX), as neither of these were tested.
KM-resistant specimens were considered CPM-sus-
ceptible if CPM DST showed susceptibility or was
unknown, and vice versa. We calculated PZA
treatment through days of prescribed PZA.
We defined PZA treatment as a full PZA-contain-
ing intensive phase as PZA treatment on 780% of
days during the intensive phase, a partial PZA
regimen as ,80% of days in the intensive phase, an
incomplete PZA regimen as 716% but ,80% of
days in the intensive phase, and no PZA treatment as
,16% of days in the intensive phase (equivalent to
,30 days in a 6-month intensive phase). All outcomes
were based on the WHO 2013 definitions.26 A 6-
month cut-off was used until the outcome ‘failure due
to culture conversion and culture reversion’ could be
declared, as this was the defined intensive phase;
‘failure due to acquired resistance’ could be declared
at any time.26 ‘Death’ and ‘loss to follow-up (LTFU)’
were defined according to programme decisions,
unless a patient had been defined as ‘failure’ earlier
during treatment.
Data management and analysis
We used a retrospective cohort study design and
multivariable logistic regression. The primary analy-
sis in patients receiving a full PZA-containing
intensive phase with known PZA DST results was
used to calculate the odds ratio (OR) of a successful
outcome (cure or treatment completed) for PZA
*The appendix is available in the online version of this article, at
http://www.ingentaconnect.com/content/iuatld/ijtld/2018/
00000022/00000005/art00014
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susceptibility compared with resistance. A successful
outcome was compared with unsuccessful outcomes
(failure or death). We decided a priori to include the
variables sex, age, previous use of first-line drugs
(FLDs) RMP, INH, EMB, PZA and SM, and presence
of cavities on chest X-ray, which are commonly
associated with treatment outcome and are adjusted
for in other studies.19,22,28 We also included year of
treatment initiation to account for unmeasured time-
dependent effects. The secondary analysis assessed
the association between successful outcome and
duration of PZA treatment, first among patients
without diagnostic PZA DST results and then among
patients with PZA resistance. We restricted the
analysis to patients with no PZA DST results to
reduce bias,29 as a PZA DST result could guide
clinical decisions. The same analyses could not be
performed in patients with PZA susceptibility at
diagnosis due to low numbers.
In the descriptive analysis, we used the v2 test for
statistical testing for categorical variables and the
Wilcoxon rank-sum test for continuous variables. We
used the Wald test in the crude and multivariable
models, and the likelihood ratio test to assess interac-
tion in the final multivariable logistic models. Missing
values were included as unknown if .10% were
missing, but were otherwise coded as missing. Data
cleaning and analysis were performed using STATA
v14.1 (Stata Corporation, College Station, TX, USA).
Power calculations for the main analysis using the
available patient cohort (n¼ 508, outcomes ratio 3.5
[successful 396; death/failure 112], baseline propor-
tion of success 78%) used an OR of 1.6 for successful
outcome in PZA-susceptible compared with PZA-
resistant MDR-TB based on a meta-analysis,19 with a
two-sided likelihood ratio test and a¼0.05, yielding a
power of 40%.
Sensitivity analyses were undertaken for the
primary analysis in patients with only bacteriologi-
cally confirmed TB, receiving 76 months of treat-
ment, and only under the 2012 programme. An
additional model compared treatment success with
death/failure/LTFU.
The study fulfilled the exemption criteria of the
MSF Ethics Review Board (ERB) for a posteriori
analyses of routinely collected clinical data, and did
not require MSF ERB review.30 The study was
conducted with permission from Dr SWong (Medical
Director, MSF, Operational Centre Amsterdam, The
Netherlands). The study protocol was also approved
by the London School of Hygiene & Tropical
Medicine Research Ethics Committee, London, UK.
RESULTS
Patient characteristics
Of a total of 2593 patients, 2446 (94.3%) were
included, 832 (34.0%) of whom had a diagnostic
PZA DST result available (Appendix Figure). Table
1 shows the characteristics of the 2446 patients
included. The median treatment duration was 20
months (range 0–38), and the median duration of
PZA treatment was 12 months (range 0–34).
Isolates were resistant to a median of four drugs at
diagnosis (interquartile range 4–4); 87.2% (n ¼
2132) of the intensive phase regimens contained at
least five effective drugs. A successful outcome was
recorded in 59.4% of patients, 5.8% died, 11.9%
failed treatment and 22.9% were lost to follow-up.
A full PZA regimen was prescribed in 90.1% (1450/
1610) of patients with no available PZA DST result,
90.8% (197/217) of those with PZA-susceptible
strains and 76.6% (469/612) of those with PZA-
resistant strains (seven patients were excluded as
they had received PZA treatment only in the
continuation phase). Of patients with available
PZA DST results at diagnosis, 73.6% (612/832)
had PZA-resistant strains.
Main results
In the primary unadjusted analysis (Table 2), we
found no evidence of an association between a
successful outcome and PZA susceptibility among
patients receiving a full PZA-containing intensive
phase (odds ratio [OR] 1.04, 95% confidence interval
[CI] 0.65–1.65, P¼0.9). Patients with previous use of
FLDs (OR 0.54, 95%CI 0.31–0.93, P ¼ 0.03) and
SLDs (OR 0.55, 95%CI 0.32–0.95, P ¼ 0.03) had
approximately 45% lower odds of success. The odds
of a successful outcome decreased with increasing
numbers of drugs to which the strain was resistant at
diagnosis (OR 0.64, 95%CI 0.51–0.81 per resistant
drug, P , 0.001).
In the multivariable analysis (Table 2), there was
also no evidence of an association between a
successful outcome and PZA susceptibility (OR
0.86, 95%CI 0.51–1.44, P ¼ 0.6), after adjustment
for sex, age, previous FLD use, cavities on chest X-ray
at diagnosis, programme year and number of drugs to
which the diagnostic strain was resistant. We found
no clinically important interaction variables in the
final model. Sputum smear and previous use of SLDs
did not change the OR by more than 10% in the
multivariable model, and were not included in the
final analysis. The model comparing success with
death/failure/LTFU had comparable results (Appen-
dix Table A.2). Similar results were seen in the three
sensitivity analyses (Appendix Tables A.3–A.5).
The secondary adjusted multivariable analyses
showed no evidence of an association between
successful outcome and a full PZA-containing inten-
sive phase, either in patients with no available
baseline PZA DST results at diagnosis (OR 0.86,
95%CI 0.49–1.51, P¼0.6; Appendix Table A.6) or in
patients with PZA-resistant MDR-TB strains (OR
1.38, 95%CI 0.71–2.68, P ¼ 0.3; Appendix Table
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Table 1 Demographic and clinical characteristics of MDR-TB patients with and without a PZA DST result available and PZA-resistant
and PZA-susceptible patients
All included
patients
(n ¼ 2446, 100%)
n (%)
PZA DST result
not available
(1614/2446, 66.0)
n (%)
PZA DST result
available
(832/2446, 34.0)
n (%) P value*
PZA-resistant
(612/832, 73.6)
n (%)
PZA-susceptible
(220/832, 26.4)
n (%) P value*
Sex
Female 1257 (51.4) 834 (51.7) 423 (50.8) 318 (52.0) 105 (47.7)
Male 1189 (48.6) 780 (48.3) 409 (49.2) 0.7 294 (48.0) 115 (52.3) 0.3
Age, years,
median [IQR]
30.5 [24–42] 30 [24–41] 31 [24–42] 0.2 31 [24–42] 32 [25–41.5] 0.3
Marital status
Not married 1046 (42.8) 694 (43.0) 352 (42.3) 260 (42.5) 92 (41.8)
Married 1400 (57.2) 920 (57.0) 480 (57.7) 0.7 352 (57.5) 128 (58.2) 0.9
Employment status
Other† 1099 (44.9) 714 (44.2) 385 (46.3) 284 (46.4) 101 (45.9)
Unemployed 1347 (55.1) 900 (55.8) 447 (53.7) 0.3 328 (53.6) 119 (54.1) 0.9
Body mass index, kg/m2
Normal (718.5) 1156 (47.3) 764 (47.3) 392 (47.1) 297 (48.5) 95 (43.2)
Underweight (,18.5) 1290 (52.4) 850 (52.7) 440 (52.9) 0.9 315 (51.5) 125 (56.8) 0.2
TB programme
2003 852 (34.8) 673 (41.7) 179 (21.5) 115 (18.8) 64 (29.1)
2009 844 (34.5) 601 (37.2) 243 (29.2) 199 (32.5) 44 (20.0)
2012 750 (30.7) 340 (21.1) 410 (49.3) ,0.001 298 (48.7) 112 (50.9) ,0.001
Alcohol use‡
No 2182 (89.2) 1437 (89.0) 745 (89.5) 551 (90.0) 194 (88.2)
Yes 264 (10.8) 177 (11.0) 87 (10.5) 0.7 61 (10.0) 26 (11.8) 0.4
Diabetes
No 1130 (46.2) 527 (32.7) 603 (72.5) 455 (74.3) 148 (67.3)
Yes 105 (4.3) 63 (3.9) 42 (5.0) 35 (5.7) 7 (3.2)
Unknown 1211 (49.5) 1024 (63.4) 187 (22.5) ,0.001 122 (19.9) 65 (29.5) 0.007
Previous first-line drugs
No 309 (12.6) 132 (8.2) 177 (21.3) 123 (20.1) 54 (24.5)
Yes 2137 (87.4) 1482 (91.8) 655 (78.7) ,0.001 489 (79.9) 166 (75.5) 0.2
Previous second-line drugs
No 1931 (79.1) 1270 (78.7) 661 (79.4) 489 (79.9) 172 (78.2)
Yes 515 (21.1) 344 (21.3) 171 (20.6) 0.7 123 (20.1) 48 (21.8) 0.6
Cavities on X-ray§
No 419 (18.6) 223 (15.6) 196 (23.6) 142 (23.4) 54 (24.8)
Yes 1835 (81.4) 1206 (84.4) 629 (75.6) ,0.001 465 (76.6) 164 (75.2) 0.7
Sputum smear¶
Negative 491 (21.0) 284 (18.8) 207 (25.1) 153 (25.3) 54 (24.7)
Scanty/1þ 691 (29.6) 450 (29.7) 241 (29.2) 180 (29.8) 61 (27.9)
2þ/3þ 1155 (49.4) 779 (51.5) 376 (45.6) 0.001 272 (45.0) 104 (47.5) 0.8
Resistance pattern
MDR-TB 2054 (84.0) 1368 (84.8) 780 (93.8) 500 (81.7) 186 (84.5)
Pre-XDR-TB 392 (16.0) 246 (15.2) 146 (17.5) 0.1 112 (18.3) 34 (15.5) 0.3
Number of drugs to
which diagnostic
strain is resistant,
median [IQR]
4 [4–4] 4 [4–4] 4 [4–5] 0.003 4 [4–5] 4 [3–4] ,0.001
Median potentially effective drugs in the intensive phase#
2–4 314 (12.8) 151 (9.4) 163 (19.6) 112 (18.3) 51 (23.2)
5–6 2029 (83.0) 1388 (86.0) 641 (77.0) 479 (78.3) 162 (73.6)
7–8 103 (4.2) 75 (4.6) 28 (3.4) ,0.001 21 (3.4) 7 (3.2) 0.3
Outcome
Success 1453 (59.4) 958 (59.4) 495 (59.5) 362 (59.2) 133 (60.5)
Death 141 (5.8) 80 (5.0) 61 (7.3) 47 (7.7) 14 (6.4)
Failure 291 (11.9) 196 (12.1) 95 (11.4) 73 (11.9) 22 (10.0)
Loss to follow-up 561 (22.9) 380 (23.5) 181 (21.8) 0.09 130 (21.2) 51 (23.2) 0.8
*v2 test for categorical and Wilcoxon rank sum test for continuous variables.
† Including the following categories: employed, retired, student, housework, disabled.
‡ Self-reported.
§Missing values, n¼ 192.
¶Missing values, n¼ 109.
#Median of monthly number of potentially effective drugs, except PZA, in the intensive phase, with all drugs counted as 1.
MDR-TB¼multidrug-resistant TB; PZA ¼ pyrazinamide; DST¼ drug susceptibility testing; IQR¼ interquartile range; TB¼ tuberculosis; XDR¼ extensively drug-
resistant TB.
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A.6). Results were similar for patients who were
treated with an incomplete PZA regimen or a full
PZA-containing intensive phase compared with no
PZA treatment among those with no PZA DST result
and those with PZA-resistant MDR-TB strains. The
same analyses using the death/failure/LTFU model
had comparable results (Appendix Table A.7).
DISCUSSION
This is the largest single-site study to assess the impact
of PZA resistance and treatment duration on treat-
ment outcome in patients with MDR-TB. We found
no evidence of an association between a successful
outcome and PZA susceptibility among MDR-TB
Table 2 Crude and adjusted analyses of the effect of PZA susceptibility and other exposure variables on treatment outcome among
patients treated with a full PZA-containing intensive phase
Death/failure
(112/508, 22.0)*
n (%)
Success
(396/508, 78.0)*
n (%) OR (95%CI) P value† aOR (95%CI)‡ P value†
Pyrazinamide
Resistant 80 (22.2) 280 (77.8) 1.00
Susceptible 32 (21.6) 116 (78.4) 1.04 (0.65–1.65) 0.9 0.86 (0.51–1.44) 0.6
Sex
Female 63 (22.6) 216 (77.4) 1.00
Male 49 (21.4) 180 (78.6) 1.07 (0.70–1.63) 0.7 1.04 (0.67–1.61) 0.9
Age, years,
median [IQR]
32 [26.0–43.5] 30 [23.5–41.5] 0.99 (0.97–1.00) 0.06 0.99 (0.97–1.00) 0.07
Previous outcome
Other 83 (20.4) 324 (79.6) 1.00
Loss to follow-up 6 (46.2) 7 (53.8) 0.30 (0.10–0.91) 0.03
Failure 23 (26.1) 65 (73.9) 0.72 (0.42–1.23) 0.2
TB programme
2003 12 (20.3) 47 (79.7) 1.00
2009 42 (27.1) 113 (72.9) 0.69 (0.33–1.42) 0.3 0.58 (0.26–1.29) 0.2
2012 58 (19.7) 236 (80.3) 1.04 (0.52–2.08) 0.9 0.91 (0.41–1.99) 0.8
Diabetes
No 90 (21.5) 328 (78.5) 1.00
Yes 9 (37.5) 15 (62.5) 0.46 (0.19–1.08) 0.07
Unknown 13 (19.7) 53 (80.3) 1.12 (0.58–2.14) 0.7
Previous first-line drugs
No 18 (14.8) 104 (85.2) 1.00
Yes 94 (24.4) 292 (75.6) 0.54 (0.31–-0.93) 0.03 0.55 (0.31–0.99) 0.05
Previous second-line drugs
No 88 (20.4) 344 (79.6) 1.00
Yes 24 (31.6) 52 (68.4) 0.55 (0.32–0.95) 0.03
Cavities on X-ray
No 26 (18.6) 114 (81.4) 1.00
Yes 86 (23.4) 282 (76.6) 0.75 (0.46–1.22) 0.3 0.83 (0.49–1.39) 0.5
Sputum smear§
Negative 18 (12.9) 121 (87.1) 1.00
Scanty/1þ 40 (23.5) 130 (76.5) 0.48 (0.26–0.89) 0.02
2þ/3þ 53 (26.9) 144 (73.1) 0.40 (0.22–0.73) 0.002
Resistance pattern
MDR-TB 84 (19.6) 344 (80.4) 1.00
Pre-XDR-TB 28 (35.0) 52 (65.0) 0.45 (0.27–0.76) 0.003
Number of drugs to
which diagnostic
strain is resistant,
median [IQR]
4 [4–5] 4 [4–4] 0.64 (0.51–0.81) ,0.001 0.64 (0.50–0.81) ,0.001
Median potentially effective drugs in the intensive phase¶
2–4 24 (21.4) 88 (78.6) 1.00
5–6 77 (20.5) 298 (79.5) 1.06 (0.63–1.77) 0.8
7-8 11 (52.4) 10 (47.6) 0.25 (0.09–0.65) 0.005
Ofloxacin treatment
No 100 (22.3) 349 (77.7) 1.00
Yes 12 (20.3) 47 (79.7) 1.12 (0.57–2.20) 0.7
*Of 651 patients with outcome death/failure/cure/treatment completed, 142 excluded due to no PZA treatment in the full intensive phase, one patient excluded
due to unknown X-ray result.
†Wald test.
‡ Adjusted for age, sex, previous first-line drugs, cavities on X-ray, programme year and number of drugs to which strain was resistant at diagnosis.
§ Two missing values due to unknown smear result.
¶Median monthly number of potentially effective drugs, except PZA, in intensive phase, with all drugs counted as 1.
PZA¼pyrazinamide; OR¼odds ratio; CI¼ confidence interval; aOR¼adjusted OR; IQR¼ interquartile range; TB¼ tuberculosis; MDR-TB¼multidrug-resistant TB;
XDR-TB¼ extensively drug-resistant TB.
548 The International Journal of Tuberculosis and Lung Disease
patients treated with a standard full PZA-containing
intensive phase of a WHO-recommended regimen in
a high MDR-TB burden setting. There was no
evidence of an association between a successful
outcome and PZA treatment duration in the intensive
phase.
The main result was unexpected, and did not
support our hypothesis that a treatment regimen with
a full PZA-containing intensive phase would improve
treatment outcomes in patients with PZA-susceptible
strains compared with PZA-resistant strains. Our
results are therefore consistent with two smaller
previous primary studies,20,21 but not with the meta-
analysis and another small primary study from
Peru.19,31
Several explanations could be postulated. Even
with the inclusion of all eligible patients for more
than one decade, the sample size had low power for
the main analysis. The retrospective and observation-
al nature of the study contributed to an increased risk
of bias. Prescription of a full PZA-containing
intensive phase could also have been influenced by
PZA DST results or other associated baseline
characteristics, resulting in selection bias, although
clear protocols were in use to routinely include PZA
in MDR-TB regimens.
The main effect of PZA may be its contribution to
shortening the duration of treatment,32,33 rather than
improving the outcome of an already lengthy
regimen. This would also support the improved result
of the shortened treatment regimen now recommend-
ed by the WHO that includes PZA.4 Patients might
also have had sufficient likely effective drugs in their
regimen (87.2% had five or more likely effective
drugs in the intensive phase; Table 1), rendering
additional PZA redundant.22
The secondary analysis also showed insufficient
evidence of an association between a successful
outcome and a full PZA-containing intensive phase
among patients with unknown PZA DST results and
those with PZA-resistant MDR-TB strains. A possible
explanation in the former could be the high back-
ground PZA resistance in MDR-TB patients in
Karakalpakstan (73.6%; Table 1). Optimal PZA
treatment duration in MDR-TB may be longer than
the 2 months used for drug-susceptible TB6 due to the
lower efficacy of SLDs. This effect could be limited to
patients with PZA-susceptible MDR-TB strains, but
PZA-resistant strains might also benefit, due to a
synergistic effect with other drugs.34 We did not find
that a different duration of PZA treatment in the
intensive phase was associated with greater odds of a
successful outcome, although some numbers were
small (Appendix Table A.6).
The generalisability of this study would be limited
to settings with low HIV prevalence and high
background prevalence of SLD resistance, as in other
former Soviet Union countries. Caution is needed
when extrapolating the results to other settings, as
background resistance patterns might be expected to
change the impact of PZA treatment. Furthermore,
these results refer to a background standardMDR-TB
regimen, but might not be applicable to newer
regimens.
The main limitation of our study was the low
power for the main analysis and the risk of bias due to
the observational study design. Although we used
both restriction and stratification, bias cannot be
accounted for in the analysis. Patients were included
over a long time, and unmeasured factors could lead
to residual confounding, although we adjusted for
programme year. Another limitation was the deter-
mination of PZA susceptibility using MGIT, with
possible false resistance, which could have affected
the results. Furthermore, adjustment was made for
initial PZA DST results, but not for acquired PZA
resistance during treatment. Another limitation was
the way in which potentially effective drugs were all
counted as 1; we were unable to justify the
assignment of differential weights.
Nevertheless, because this was the first large
primary study with these findings, with all the
associated limitations of a retrospective observational
cohort, cautious consideration should be made before
changing treatment protocols. A clinical trial assess-
ing the effect of PZA inclusion and treatment
duration could address this question, but might not
be regarded as a priority in the current arena. An
updated meta-analysis including this full cohort
would be worthwhile.
CONCLUSIONS
The present study provided provocative but insuffi-
cient evidence to warrant changing PZA treatment
protocols, although the evidence relating to PZA for
the WHO 2016 guidelines was weak. Until further
evidence supporting these findings emerges, it seems
prudent to continue including PZA in standard
MDR-TB regimens unless resistance is certain.
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APPENDIX
Drug groups for the treatment of multidrug-resistant
tuberculosis according to World Health Organization
2016 guidelines.26
Group A: Levofloxacin, moxifloxacin, gatifloxacin
Group B: Amikacin, kanamycin, capreomycin (strep-
tomycin)
Group C: Ethionamide/prothionamide, cycloserine/
terizidone, linezolid, clofazimine
Group D:
D1: Pyrazinamide, ethambutol, high-dose isoniazid
D2: Bedaquiline, delamanid
D3: Para-aminosalicylic acid, imipenem-cilastin,
meropenem, amoxicillin-clavulanate, thioace-
tazone.
Figure Flow diagram of the inclusion and exclusion criteria of patients from the DR-TB treatment
programme in Karakalpakstan, Uzbekistan. MDR-TB ¼ multidrug-resistant tuberculosis; DST ¼
drug susceptibility testing; WHO¼World Health Organization; HIV¼ human immunodeficiency
virus; XDR-TB¼ extensively drug-resistant tuberculosis; PZA¼ pyrazinamide.
Table A.1 Methods and location of DST used by the DR-TB programme in Karakalpakstan,
Uzbekistan
DST method
Supranational
Reference Laboratory,
Borstel, Germany Laboratory in Karakalpakstan
Culture-based DST, except PZA
MGIT* 2003–2007 2007 onwards
Lo¨wenstein-Jensen† NA 2003 onwards
PZA DST method
MGIT* Routinely conducted
between 2003–2006
Started November 2010, routinely
conducted from 2012 onwards
* BACTECE MGITE 960 system (BD Biosciences, Sparks, MD, USA).
† Proportion method.
DST ¼ drug susceptibility testing; DR-TB ¼ drug-resistant tuberculosis; PZA ¼ pyrazinamide; MGIT ¼ Mycobacteria
Growth Indicator Tube.
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Table A.2 Crude and adjusted analyses of the effect of PZA susceptibility and other exposure variables on treatment outcome
among patients treated with a regimen with PZA throughout the intensive phase: death/failure/LTFU model
Death/failure/LTFU
n (%)
Success
n (%) OR (95%CI) P value* aOR (95%CI)† P value*
Pyrazinamide 267/663* (40.3) 396/663* (59.7)
Resistant 188 (40.2) 280 (59.8) 1.00
Susceptible 79 (40.5) 116 (59.5) 0.99 (0.70–1.39) 0.9 0.80 (0.56–1.17) 0.3
Sex
Female 121 (35.9) 216 (64.1) 1.00
Male 146 (44.8) 180 (55.2) 0.69 (0.51–0.94) 0.02 0.67 (0.49–0.93) 0.02
Age, years,
median [IQR]
32 [25–43] 30 [23.5–41.5] 0.99 (0.98–1.00) 0.05 0.99 (0.98–1.00) 0.08
Previous outcome
Other 206 (38.9) 324 (61.1) 1.00
LTFU 13 (65.0) 7 (35.0) 0.34 (0.13–0.87) 0.03
Failure 48 (42.5) 65 (57.5) 0.86 (0.57–1.30) 0.5
TB programme
2003 21 (30.9) 47 (69.1) 1.00
2009 99 (46.7) 113 (53.3) 0.51 (0.29–0.91) 0.02 0.42 (0.22–0.79) 0.007
2012 147 (38.4) 236 (61.6) 0.72 (0.41–1.25) 0.3 0.61 (0.33–1.13) 0.1
Diabetes
No 223 (40.5) 328 (59.5) 1.00
Yes 22 (59.5) 15 (40.5) 0.46 (0.24–0.91) 0.03
Unknown 22 (29.3) 53 (70.7) 1.12 (0.58–2.14) 0.07
Previous first-line drugs
No 61 (37.0) 104 (63.0) 1.00
Yes 206 (41.4) 292 (58.6) 0.83 (0.58–1.20) 0.3 0.83 (0.57–1.22) 0.3
Previous second-line drugs
No 227 (39.8) 344 (60.2) 1.00
Yes 40 (43.5) 52 (56.5) 0.86 (0.55–1.34) 0.5
Cavities on X-ray
No 65 (36.3) 114 (63.7) 1.00
Yes 202 (41.7) 282 (58.3) 0.80 (0.56–1.13) 0.2 0.81 (0.56–1.18) 0.3
Sputum smear‡
Negative 66 (35.3) 121 (64.7) 1.00
Scanty/1þ 86 (39.8) 130 (60.2) 0.82 (0.55–1.24) 0.4
2þ/3þ 114 (44.2) 144 (55.8) 0.69 (0.47–1.02) 0.06
Resistance pattern
MDR-TB 217 (38.7) 344 (61.3) 1.00
Pre-XDR-TB 50 (49.0) 52 (51.0) 0.66 (0.43–1.00) 0.05
Number of drugs to
which diagnostic
strain is resistant,
median [IQR]
4 [4–5] 4 [4–4] 0.76 (0.63–0.91) 0.002 0.74 (0.62–0.89) 0.002
Median potentially effective drugs in the intensive phase§
2–4 49 (35.8) 88 (64.2) 1.00
5–6 205 (40.8) 298 (59.2) 0.81 (0.55–1.20) 0.3
7–8 13 (56.5) 10 (43.5) 0.43 (0.17–1.05) 0.06
Ofloxacin treatment
No 246 (41.3) 349 (58.7) 1.00
Yes 21 (30.9) 47 (69.1) 1.58 (0.92–2.71) 0.1
*Wald test.
† Adjusted for age, sex, previous first-line drug, cavities on X-ray, programme year and number of drugs to which strain is resistant at diagnosis.
*Of 832 patients with PZA DST available at diagnosis, 166 were excluded because they received no PZA in the intensive phase and three due to unknown X-ray
results.
‡ Two missing values due to unknown smear result.
§Median number of potentially effective drugs per month, except PZA, in the intensive phase, with all drugs counted as 1.
PZA¼pyrazinamide; LTFU¼ loss to follow-up; OR¼odds ratio; CI¼confidence interval; aOR¼adjusted OR; IQR¼ interquartile range; TB¼ tuberculosis; MDR-TB¼
multidrug-resistant TB; XDR-TB¼ extensively drug-resistant TB; DST¼ drug susceptibility testing.
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Table A.3 Crude and adjusted analyses of the effect of PZA susceptibility on treatment outcome among patients treated with a full
PZA-containing intensive phase and who had bacteriologically confirmed TB:* death/failure model
Death/failure
n (%)
Success
n (%) OR (95%CI) P value† aOR (95%CI)‡ P value†
Pyrazinamide 82/368§ (22.3) 286/368§ (77.7)
Resistant 60 (22.2) 210 (77.8) 1.00
Susceptible 22 (21.4) 76 (77.6) 0.99 (0.57–1.72) 1.0 0.87 (0.48–1.59) 0.7
* Sputum submitted between 30 days before and 7 days after starting treatment.
†Wald test.
‡ Adjusted for age, sex, previous first-line drugs, cavities on X-ray, programme year and number of drugs to which strain was resistant at diagnosis.
§ Of 579 patients with PZA DSTresult available and bacteriologically confirmed TB, 94 were excluded as they received no PZA in the intensive phase, and 117 due to
loss to follow-up.
PZA¼ pyrazinamide; TB¼ tuberculosis; OR¼ odds ratio; CI¼ confidence interval; aOR¼ adjusted OR; DST¼ drug susceptibility testing.
Table A.4 Crude and adjusted analyses of the effect of PZA susceptibility on treatment outcome among patients treated with a full
PZA-containing intensive phase who had confirmed receipt of at least 6 months of treatment: death/failure model
Death/failure
n (%)
Success
n (%) OR (95%CI) P value* aOR (95%CI)† P value*
Pyrazinamide 81/477‡ (17.0) 396/477‡ (83.0)
Resistant 58 (17.2) 280 (82.8) 1.00
Susceptible 23 (16.5) 116 (83.5) 1.04 (0.62–1.77) 0.9 0.97 (0.54–1.74) 0.9
*Wald test.
† Adjusted for age, sex, previous first-line drugs, cavities on X-ray, programme year and number of drugs to which strain was resistant at diagnosis. Model with
PZA-resistant strains at diagnosis: also adjusted for previous outcome.
‡Of 667 patients with PZA DST result available who had at least 6 months of total treatment, 135 were excluded beacause they received no PZA in the intensive
phase, 1 due to unknown X-ray results and 54 due to loss to follow-up.
PZA¼ pyrazinamide; OR¼ odds ratio; CI¼ confidence interval; aOR¼ adjusted OR; DST¼ drug susceptibility testing.
Table A.5 Crude and adjusted analyses of the effect of PZA susceptibility on treatment outcome among patients treated with a full
PZA-containing intensive phase who started in the 2012 programme: death/failure model
Death/failure
n (%)
Success
n (%) OR (95%CI) P value* aOR (95%CI)† P value*
Pyrazinamide 58/294‡ (19.7) 236/294‡ (80.3)
Resistant 44 (20.4) 172 (79.6) 1.00
Susceptible 14 (17.6) 64 (82.1) 1.17 (0.60–2.28) 0.6 1.03 (0.51–2.08) 0.9
*Wald test.
† Adjusted for age, sex, previous first-line drugs, cavities on X-ray, programme year and number of drugs to which strain was resistant at diagnosis. Model with
PZA-resistant strains at diagnosis: also adjusted for previous outcome.
‡Of 410 patients with PZA DSTresults available who started in the 2012 programme, 24 were excluded because they did not receive PZA in the intensive phase and
92 because they were lost to follow-up.
PZA¼ pyrazinamide; OR¼ odds ratio; CI¼ confidence interval; aOR¼ adjusted OR; DST¼ drug susceptibility testing.
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Table A.6 Crude and adjusted analyses of effect of PZA regimen received on treatment outcome among patients with no available
PZA DST results at diagnosis and among patients with PZA-resistant strains at diagnosis: two PZA treatment duration models
Death/failure
n (%)
Success
n (%) OR (95%CI) P value* aOR (95%CI)† P value*
PZA DST results at diagnosis not available 247/1114‡ (22.2) 867/1114‡ (77.8)
Partial and full PZA regimen
Partial (,80% in the intensive phase) 18 (18.9) 77 (81.1) 1.00
Full PZA regimen (780% in the
intensive phase)
229 (22.5) 790 (77.5) 0.81 (0.47–1.38) 0.4 0.86 (0.9–1.51) 0.6
None, incomplete and full PZA regimen in the intensive phase
None (,16% in the intensive phase)§ 14 (18.4) 62 (81.6) 1.00
Incomplete (716% and ,80%)¶ 4 (21.1) 15 (78.9) 0.85 (0.24–2.94) 0.8 0.80 (0.22–2.94) 0.7
Full PZA regimen (780% in the
intensive phase)
229 (22.5) 790 (77.5) 0.78 (0.43–1.42) 0.4 0.82 (0.43–1.55) 0.5
PZA-resistant strains at diagnosis 119/480# (24.8) 361/480 (75.2)
Partial and full PZA regimen
Partial (,80% in the intensive phase) 39 (32.5) 81 (67.5) 1.00
Full PZA regimen (780% in the
intensive phase)
80 (22.2) 280 (77.8) 1.69 (1.07–2.66) 0.03 1.38 (0.71–2.68) 0.3
None, incomplete and full PZA regimen** in the intensive phase
None (,16% in the intensive phase)§ 12 (27.3) 32 (72.7) 1.00
Incomplete (716% and ,80%)¶ 27 (35.5) 49 (64.5) 0.68 (0.30–1.53) 0.4 0.51 (0.20–1.32) 0.2
Full PZA regimen (780% in the
intensive phase)
80 (22.2) 280 (77.8) 1.31 (0.65–2.67) 0.5 0.80 (0.29–2.23) 0.7
*Wald test.
† Adjusted for age, sex, previous first-line drugs, cavities on X-ray, programme year and number of drugs to which strain was resistant at diagnosis.
‡ Of 1614 patients with no available PZA DST at diagnosis; 157 excluded as PZA DST had not been defined as diagnostic before starting treatment; four because
they were given PZA treatment only in the continuation phase; and 339 due to LTFU.
§,16% of days in the intensive phase (equivalent to ,30 days in a 6-month intensive phase).
¶716% but ,80% of days in the intensive phase.
#Of 612 patients with PZA-resistant MDR-TB strains at diagnosis, 127 excluded due to outcome LTFU and five patients due to unknown X-ray result out.
**Also adjusted for median potentially effective drugs in the intensive phase.
PZA¼ pyrazinamide; DST¼ drug susceptibility testing; OR¼ odds ratio; CI¼ confidence interval; aOR¼ adjusted OR; MDR-TB¼multidrug-resistant tuberculosis;
LTFU¼ loss to follow-up.
Table A.7 Crude and adjusted analyses of the effect of PZA regimen received on treatment outcome among patients with no PZA
DST result available at diagnosis and among patients with PZA-resistant strains at diagnosis: two PZA treatment length models
Death/failure/LTFU
n (%)
Success
n (%) OR (95%CI) P value* aOR (95%CI)† P value*
PZA DST result at diagnosis not available 586/1453‡ (40.3) 867/1453‡ (59.7)
Partial and full PZA regimen
Partial (,80% in the intensive phase) 48 (38.4) 77 (61.6) 1.00
Full PZA regimen (780% in the
intensive phase)
538 (40.5) 790 (59.5) 0.92 (0.63–1.33) 0.6 0.95 (0.63–1.41) 0.8
None, incomplete and full PZA regimen in the intensive phase
None (,16% in the intensive phase)§ 35 (36.1) 62 (63.9) 1.00
Incomplete (716% and ,80%)¶ 13 (46.4) 15 (53.6) 0.65 (0.28–1.52) 0.3 0.59 (0.24–1.42) 0.2
Full PZA regimen (780% in the
intensive phase)
538 (40.5) 790 (59.5) 0.83 (0.54–1.27) 0.4 0.84 (0.53–1.31) 0.4
PZA-resistant strains at diagnosis 246/607# (40.5) 361/607# (59.5)
Partial and full PZA regimen
Partial (,80% in the intensive phase) 58 (41.7) 81 (58.3) 1.00
Full PZA regimen (780% in the
intensive phase)
188 (40.2) 280 (59.8) 1.07 (0.73–1.57) 0.7 1.14 (0.66–1.96) 0.6
None, incomplete and full PZA regimen in the intensive phase
None (,16% in the intensive phase)§ 17 (34.7) 32 (65.3) 1.00
Incomplete (716% and ,80%)¶ 41 (45.6) 49 (54.4) 0.63 (0.31–1.30) 0.2 0.61 (0.27–1.36) 0.2
Full PZA regimen (780% in the
intensive phase)
188 (40.2) 280 (59.8) 0.79 (0.43–1.47) 0.5 0.77 (0.33–1.78) 0.5
*Wald test.
† Adjusted for age, sex, previous first-line drugs, cavities on X-ray, programme year and number of drugs to which strain was resistant at diagnosis. Model with
PZA-resistant strains at diagnosis: also adjusted for previous outcome.
‡ 157 excluded as PZA DST had not been defined as diagnostic before starting treatment and four because they were given PZA treatment only in the continuation
phase.
§,16% of days in the intensive phase (equivalent to ,30 days in a 6-month intensive phase period).
¶716% but ,80% of days in the intensive phase.
# Five patients excluded due to unknown X-ray results.
PZA¼ pyrazinamide; LTFU¼ loss to follow-up; OR¼ odds ratio; CI¼ confidence interval; aOR¼ adjusted OR; DST¼ drug susceptibility testing.
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R E´ S U M E´
CON T E X T E : L’Organisation Mondiale de la Sante´
(OMS) recommande l’inclusion du pyrazinamide
(PZA) dans les protocoles de traitement de la
tuberculose multire´sistante (TB-MDR) sauf si la
re´sistance au PZA est certaine.
OB J E C T I F : Examiner l’association entre sensibilite´ au
PZA et re´sultat du traitement de la TB-MDR parmi les
patients traite´s avec un protocole PZA et voir si la dure´e
de la phase intensive du traitement par PZA a affecte´ les
re´sultats du traitement.
S CH E´MA : Nous avons re´alise´ une e´tude re´trospective
de cohorte, incluant tous les patients TB-MDR e´ligibles
ayant commence´ leur traitement en 2003–2013 au sein
du programme TB a` Karakalpakstan, Ouzbe´kistan. Le
test de pharmacosensibilite´ (DST) au PZA a recouru a` la
culture en milieu liquide et les re´sultats ont e´te´ classe´s en
fonction des de´finitions 2013 de l’OMS.
R E´ S U LTAT S : Sur 2446 patients TB-MDR inclus, 832
(34,0%) disposaient d’un DST au PZA de de´part, dont
612 (73,6%) ont e´te´ re´sistants au PZA. Nous n’avons
pas trouve´ d’association entre le succe`s du traitement et
la sensibilite´ au PZA (OR ajuste´ [ORa] 0,86 ; IC95%
0,51–1,44 ; P¼0,6) chez les patients traite´s par PZA. De
plus, aucune preuve n’a mis en e´vidence une association
entre succe`s du traitement et dure´e du traitement par
PZA (ORa 0,86 ; IC95% 0,49–1,51 ; P¼ 0,6) parmi les
patients sans DST au PZA de de´part.
CONC LU S I ON : Le traitement de la TB-MDR avec un
protocole standard de PZA ne semble pas ame´liorer les
re´sultats du traitement, quelles que soient la sensibilite´
au PZA ou la dure´e du traitement.
R E S UM E N
MARCO DE R E F E R ENC I A: La Organizacio´n Mundial de
la Salud (OMS) recomienda que se incluya la
pirazinamida (PZA) en las pautas de tratamiento de la
tuberculosis multirresistente (TB-MDR), a menos de
que exista certeza sobre la resistencia.
OB J E T I VO: Investigar la asociacio´n entre la sensibilidad
a la PZA y el desenlace del tratamiento de la TB-MDR
en los pacientes que reciben una pauta con PZA y
determinar si la duracio´n de la fase intensiva del
tratamiento con PZA tiene algu´n efecto sobre el
desenlace terape´utico.
M E´ TODO: Se llevo´ a cabo un estudio de cohortes
retrospectivo de todos los pacientes con TB-MDR que
cumplı´an los requisitos y habı´an iniciado tratamiento del
2003 al 2013 en el marco del programa contra la
tuberculosis en Karakalpakista´n, en Uzbekista´n. Se
practico´ la prueba de sensibilidad a PZA en medio
lı´quido y los desenlaces se clasificaron segu´n las
definiciones de la OMS del 2013.
R E SU LTADOS: De los 2446 pacientes con TB-MDR
incluidos, 832 contaban con una prueba inicial de
sensibilidad a PZA (34,0%) y de ellos, 612 eran
resistentes a PZA (73,6%). No se observo´ ninguna
asociacio´n entre el e´xito terape´utico y la sensibilidad a
PZA en los pacientes que recibieron un tratamiento con
PZA (OR ajustado [ORa] 0,86; IC95% 0,51–1,44; P¼
0,6). Adema´s, no se encontraron indicios de una
asociacio´n entre el e´xito terape´utico y la duracio´n del
tratamiento con PZA en los pacientes que no contaban
con una prueba inicial de resistencia a PZA (ORa 0,86;
IC95% 0,49–1,51; P¼ 0,6).
CONC LU S I O´ N: El tratamiento de la TB-MDR con una
pauta corriente que contiene PZA no parece mejorar los
desenlaces terape´uticos, sea cual fuere la situacio´n frente
a la sensibilidad a PZA o la duracio´n de su
administracio´n.
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